Amneal Pharmaceuticals Inc. has received approval from the FDA for its Abbreviated New Drug Application for lenalidomide capsules in 2.5-, 5-, 10-, 15-, 20- and 25-mg strengths. In settlement of all outstanding claims related to this product, Celgene agreed to provide Amneal with a license to Celgene’s patents required to manufacture and sell generic lenalidomide in the United States beginning on Jan. 31, 2026. Lenalidomide is indicated for the treatment of several blood cancers.
MARCH 5, 2025